Drug Profile
Apremilast - Amgen
Alternative Names: AMG-407; CC-10004; CC-1004; OTEZLALatest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Amgen; Baylor Research Institute; Celgene Corporation; Erasmus MC
- Class Acetamides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
- Phase III Ankylosing spondylitis; COVID 2019 infections; Immunological disorders; Juvenile rheumatoid arthritis; Palmoplantar pustulosis; Psoriasis
- Phase II Atopic dermatitis; Bullous pemphigoid; Eczema; Female genital diseases; Hidradenitis suppurativa; Ulcerative colitis
- No development reported Rheumatoid arthritis
- Discontinued Asthma; Cancer; Crohn's disease
Most Recent Events
- 09 Mar 2024 Efficacy and safety data from phase III trial in Palmoplantar pustulosis released by Amgen
- 09 Mar 2024 Updated efficacy results from the phase III SPROUT trial in Plaque psoriasis released by Amgen
- 11 Dec 2023 Amgen initiates the phase-III ESSENCE trial for Plaque psoriasis in China (PO) (NCT06122649)